TNFRSF4 and neoplasm: More importantly, systemic administrations of anti-PD-1 + anti-CTLA-4 Abs with PL1-OX40 (ψ) + anti-OX40 Ab dramatically reduced the tumor metastasis in the lung metastasis model.